Curasight’s CEO Ulrich Krasilnikoff comments:

"It has been a busy first nine months of the year for Curasight as we progressed our pipeline of products under our theranostic platform, combining uTRACE^® diagnostics and uTREAT^® therapy with the aim of providing improved cancer management.

We believe in ‘what you see is what you treat’ and we therefore were pleased as part of this theranostic approach, to initiate pre-clinical studies testing our uTREAT^® product in neuroendocrine tumours (NET) and head and neck cancer to add to clinical data we already have from studies with our uTRACE^® diagnostic product."

Q3 (July – September) 2022

• Net sales amounted to 0 (0) DKK
• Operating profit/loss amounted to -1,602,143 (-807,809) DKK
• Profit/loss before taxes amounted to -4,504,912 (-1,418,449) DKK
• Profit/loss for the period amounted to -3,513,832 (-1,106,390) DKK
• Total assets amounted to 95,748,009 (59,506,515) DKK
• Equity ratio amounted to 96,2 (94.8) %.
• Earnings per share amounted to -0,17 (-0.06) DKK

Q1-Q3 (January – September) 2022

• Net sales amounted to 0 (0) DKK
• Operating profit/loss amounted to -4,299,561 (-1,579,771) DKK
• Profit/loss before taxes amounted to -8,997,274 (-3,495,177) DKK
• Profit/loss for the period amounted to -7,017,874 (-2,726,238) DKK
• Total assets amounted to 95,748,009 (59,506,515) DKK
• Equity ratio amounted to 96,2 (94.8) %.
• Earnings per share amounted to -0,35 (-0.16) DKK

Highlights during the third quarter

• On August 25, Ulrich Krasilnikoff and Andreas Kjær presented the company and the Q2 2022 report at HC Andersen Capital.
   
• On September 4, Curasight announced that the company’s CDO Hanne Damgaard Jensen had purchased 7,600 shares at an aggregated volume price of 97,964 DKK on November 1, 2022. Hanne Damgaard Jensen total holdings in Curasight A/S after the purchase of the shares is 35,000 shares.

Highlights after the period

• On October 13, Curasight announced that it has initiated pre-clinical studies of uPAR targeted radionuclide therapy (uTREAT®) in head and neck cancer and in neuroendocrine tumors (NET). Results are expected to be available during 1H 2023.
• On November  21, Ulrich Krasilnikoff and Andreas Kjær presented the company and the strategy at SEB Healthcare Seminar 2022.

For more information regarding Curasight, please contact:

Ulrich Krasilnikoff, CEO Phone: +45 22 83 01 60

E-mail: uk@curasight.com

www.curasight.com

Curasight is a clinical development company based in Copenhagen, Denmark. The Company is a pioneer in the field of exploiting a novel Positron Emissions Tomography (PET) imaging platform targeting the urokinase-type plasminogen activator receptor ("uPAR"). The technology provides improved diagnosis and risk stratification in multiple cancer types.